Newron Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference in New York

MILAN, Italy & MORRISTOWN, N.J.--()--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 2018 Cantor Global Healthcare Conference in New York, NY, on Wednesday, October 3 at 3:25 p.m. ET.

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com

Contacts

For more information:
Newron
Stefan Weber – CEO
+39 02 6103 46 26
pr@newron.com
or
UK/Europe
Julia Phillips / Natalie Garland-Collins, FTI Consulting
+44 20 3727 1000
SCnewron@fticonsulting.com
or
Switzerland
Martin Meier-Pfister, IRF Communications
+41 43 244 81 40
martin.meier-pfister@irfcom.ch
or
Germany/Europe
Anne Hennecke, MC Services
+49 211 52925222
anne.hennecke@mc-services.eu
or
USA
Paul Sagan, LaVoieHealthScience
+1 617 374 8800, Ext. 112
psagan@lavoiehealthscience.com

Release Summary

Newron Pharmaceuticals S.p.A. (SIX: NWRN) will present at the 2018 Cantor Global Healthcare Conference in New York on October 3 at 3:25 PM.

$Cashtags

Contacts

For more information:
Newron
Stefan Weber – CEO
+39 02 6103 46 26
pr@newron.com
or
UK/Europe
Julia Phillips / Natalie Garland-Collins, FTI Consulting
+44 20 3727 1000
SCnewron@fticonsulting.com
or
Switzerland
Martin Meier-Pfister, IRF Communications
+41 43 244 81 40
martin.meier-pfister@irfcom.ch
or
Germany/Europe
Anne Hennecke, MC Services
+49 211 52925222
anne.hennecke@mc-services.eu
or
USA
Paul Sagan, LaVoieHealthScience
+1 617 374 8800, Ext. 112
psagan@lavoiehealthscience.com